Myelofibrosis historical perspective: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Myelofibrosis}} | {{Myelofibrosis}} | ||
{{CMG}}{{AE}}{{ | {{CMG}}{{AE}}{{Sab}} | ||
==Overview== | ==Overview== | ||
Revision as of 20:38, 18 December 2018
|
Myelofibrosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Myelofibrosis historical perspective On the Web |
|
American Roentgen Ray Society Images of Myelofibrosis historical perspective |
|
Risk calculators and risk factors for Myelofibrosis historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sabawoon Mirwais, M.B.B.S, M.D.[2]
Overview
The first description of primary myelofibrosis (PMF) is credited to a German surgeon, Gustav Heuck, who described the concept in 1879. Additional work and discoveries started to get documented at the beginning of the twentieth century. The substantial contribution came from Max Askanazy, a German pathologist and Herbert Assmann, an Internist from Germany. The condition was given several pseudonyms before the International Working Group for Myelofibrosis Research and Treatment decided in 2006 to use the term primary myelofibrosis (PMF).
Historical Perspective
- Gustav Heuck, a German surgeon, was the first to describe the notion of myelofibrosis in 1879. He explained the idea under the title of 'Two cases of leukemia with peculiar blood and bone marrow findings'. Heuck described two patients with massive splenomegaly, increased number of morphologically abnormal leukocytes, and nucleated red blood cells. He observed that the clinical findings in these two patients were different from those described for chronic myelogenous leukemia (CML) because of the presence of bone marrow fibrosis and extensive extramedullary hematopoiesis (EMH). He also noted osteosclerosis in an autopsy report.[1]
- In 1904, Max Askanazy, a German pathologist, reported a case with significant extramedullary hematopoiesis (EMH) of the liver and diffuse bone marrow fibrosis.[2]
- In 1907, Herbert Assmann, an internist from Germany, described another case of extramedullary hematopoiesis (EMH) and bone marrow fibrosis which he went on and named ‘osteosclerotic anemia’. Later on, it was referred to as ‘Heuck–Assmann syndrome’.[2]
- In 1914, Hans Hirschfeld, a German hematologist further elaborated the splenic pathology in primary myelofibrosis (PMF).
- In 1951, William Dameshek, an internationally renowned American hematologist, grouped together primary myelofibrosis (PMF), chronic myelogenous leukemia (CML), polycythemia vera (PV), and essential thrombocythemia (ET) and classified them as 'myeloproliferative disorders'. He reasoned that a self-perpetuating trilineage myeloproliferation underlined the pathogeneses of these conditions.[3][4]
- In 1975, Murray N Silverstein, an American hematologist, published his classic monograph and described most of the modern natural history and treatment of primary myelofibrosis (PMF).[5]
References
- ↑ Ansell, Stephen (2008). Rare hematological malignancies. New York, NY London: Springer. ISBN 9780387737430.
- ↑ 2.0 2.1 Tefferi, A (2007). "The history of myeloproliferative disorders: before and after Dameshek". Leukemia. 22 (1): 3–13. doi:10.1038/sj.leu.2404946. ISSN 0887-6924.
- ↑ DAMESHEK W (April 1951). "Some speculations on the myeloproliferative syndromes". Blood. 6 (4): 372–5. PMID 14820991.
- ↑ Tefferi A (January 2008). "The history of myeloproliferative disorders: before and after Dameshek". Leukemia. 22 (1): 3–13. doi:10.1038/sj.leu.2404946. PMID 17882283.
- ↑ Silverstein, Murray (1975). Agnogenic myeloid metaplasia. Acton, Mass: Pub. Sciences Group. ISBN 088416022X.